Keros Therapeutics

Keros Therapeutics:
A leader in understanding the role of the Transforming Growth Factor-Beta family of proteins that is a master regulator of red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone. Lead protein therapeutic product candidate, KER-050, an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome (MDS) and myelofibrosis. KER-012, is designed to bind to and inhibit the signaling of TGF-β ligands that suppress bone growth, including activin A and activin B and is being developed for the treatment of PAH and for the treatment of disorders associated with bone loss, such as osteogenesis imperfecta and osteoporosis.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Hematology, Metabolic Disorders, Oncology, Rare Disease
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
99 Hayden Avenue
Suite 120 (Building E)
Lexington, MA 02421
United States
Suite 120 (Building E)
Lexington, MA 02421
United States
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Jasbir Seehra, CEO
Top 10 Holders of Keros Therapeutics, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Fidelity Management & Research Co. LLC | 13.62 | 4,028,136 | 128.42 | 13F | 6/30/23 |
OrbiMed Advisors LLC | 5.12 | 1,514,734 | 48.29 | 13F | 6/30/23 |
Alkeon Capital Management LLC (13F Subfiler) | 4.85 | 1,434,036 | 45.72 | 13F | 6/30/23 |
T Rowe Price Associates, Inc. (13F Subfiler) | 4.26 | 1,260,801 | 40.19 | 13F | 6/30/23 |
Braidwell LP | 3.87 | 1,143,865 | 36.47 | 13F | 6/30/23 |
Vanguard Group, Inc. (Subfiler) | 3.81 | 1,125,958 | 35.90 | 13F | 6/30/23 |
State Street Corp. | 3.43 | 1,015,903 | 32.39 | 13F | 6/30/23 |
Candriam Belgium SA | 3.36 | 970,027 | 30.92 | Funds | 5/31/23 |
BlackRock Fund Advisors | 3.06 | 905,984 | 28.88 | 13F | 6/30/23 |
T. Rowe Price Associates, Inc. (Investment Management) | 2.86 | 845,068 | 26.94 | Funds | 6/30/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.